The global pharmaceutical mass flow controller market is likely to reach USD XX million in 2027, from its recorded value of USD XX million in 2019.
The global pharmaceutical mass flow controller market is expected to grow at a CAGR of 6.4% during the forecasting period (2020-2027), owing to growing demand for low flow rate controlling devices for precise measurements. Increasing developments in the laboratory & biomedical research sector that require gas flow measurement under controlled conditions is expected to drive the mass flow controller market growth over the forecast period. The global pharmaceutical mass flow controller market is multiplying due to the rising need for reliable and efficient measurement of liquid and gas flow. There are many challenges faced by the pharmaceutical industry during productions of various products. Hence, precise measurements are required to control and accuracy throughout the production processes. By using mass flow controllers, pharmaceutical companies have improved the accuracy and reliability of air flow measurement; improved performance of the air handling units; and reduced installation and maintenance costs. As the medical & Pharmaceutical market is growing due to the growing aging population, the mass flow controller for the pharmaceutical industry is expected to grow with more opportunities. Current and Post-COVID-19 growth prospects in pharmaceuticals and healthcare industries are the major factors driving the growth of the pharmaceuticals mass flow controller market. Mass flow controllers play a crucial role in the quality control of different types of medical devices, and several major companies have grabbed the opportunity to fight against the deadly coronavirus pandemic. For instance, RedySmart mass flow controllers of Sierra Instruments provide critical gas flow control systems for bioreactors to scale vaccines from lab to pilot to full-scale production.
Market Dynamics
Drivers
- Growing usage of mass flow controller in the R&D of bioprocessing
- Growing production of active pharmaceutical ingredient (API) through chemical synthesis
Restraints
- Variations in differential pressure create offset in flow measurement
- MFC Instability with Downstream Pressure Fluctuations
Growing usage of mass flow controller in the R&D of bioprocessing
The mass flow controller (MFC) is commonly used in many bioprocessing systems to manage the flow of different gases into bioreactor chambers.
Intelligent MFC technology with digital-based flow-control capabilities can help deliver more precise and versatile gas flow control, more sophisticated analysis and resolution of process issues, and can also help equip bioprocess scientists and engineers with data that could lead to improved bioreactor performance. It plays an essential role in maintaining a bioreactor’s controlled environment and achieving optimal cell growth. Two critical factors that govern cell culture yield are the levels of dissolved oxygen (DO) in the bioreactor and the pH of the fermentation broth. For bioprocessing engineers, who focus on optimizing performance, controlling costs and satisfying strict regulatory requirements MFCs provide a key tool for managing specific bioreactors as well as overall bioprocessing system performance, reducing unscheduled downtime and maximizing integrity tester and bioreactor uptime and yields.
The mass flow controller (MFC) has the application of bioreactors, including fermenters, are for production of bioethanol and other biofuels, pharmaceutical products, fine chemical products, food and beverages and tissue growth. Dosing of Air, N2, O2 and CO2 into microbial and cell cultivation is critical. In addition, it is also used in tissue engineering. Basically, it aims the development of tissues and organs by means of the application of in-vitro cell culture techniques in order to grow tissues, or even full organs, which can be used to replace those of the human body which are ill or have lost its functionality. Thus, tissue engineering promises a new paradigm in the treatment of many diseases as well as to revolution the current organ transplantation scheme since, when totally developed, full new organs will be grown in-vitro to replace those damaged removing the need from donors, which is maybe the bottleneck for the application of these techniques nowadays. Thus rising technology for developing organs will also drive the market growth in the forecast period. Thus, bioprocessing has led to breakthroughs in many areas of the healthcare industry. From new products and the sophisticated use of raw materials, but also to more efficient and environmentally friendly production of known substances and necessary materials. These factors are driving the market growth in the forecast period.
Geographical Analysis
Asia-Pacific is growing at the CAGR of 6.9% during the forecast period (2020-2027).
Asia-Pacific has the second largest share of about XX% in the global pharmaceutical mass flow controller market in 2019, owing to the booming industrialization in countries including India and China. The growing pharmaceutical sector in India is a major factor which will drive the market growth in the region. Asia-Pacific pharmaceutical mass flow controller and it is estimated to grow at a CAGR of XX% during the forecast period (2020-2027) to reach a market value of USD XX million by 2027. Pharmaceutical companies are prolific in the Asia-Pacific region. There were 5,547 drugs in active development in the region and 1,509 that have been launched. Japan has the highest number of drugs in active development, nearly 2,000. Thus the growing development of pharmaceuticals in the region is driving the market growth.
As per economic and social commission for Asia and the Pacific (ESCAP), reports that the geriatric population in Asia-Pacific was around 548 million in 2019, accounting for more than half of the world’s total elderly population. It is estimated that, by 2050, Asia-Pacific may account for almost two-thirds of the world’s geriatric population. Hence, owing to the fact that the manufacturing activities of active pharmaceutical ingredients will increase in the region which will further grow the need for the pharmaceutical mass flow controller.
In the Asia-Pacific region, a large pool of population has lifestyle-related diseases, such as diabetes and obesity, which has increased the risk of cancer. This has raised the concerns levels in the societies to early diagnose the diseases, which increases the demand for medical devices in the region.
South Korea has an innovation-friendly environment, as the government is driving growth in the pharmaceutical mass flow controller sector and is pushing for an expanded presence in the market. The government provides policy loans and tax incentives for innovation and is striving to reduce approval times and increase its share of the global market, while the Korea Pharmaceutical and Bio-pharma Manufacturers Association (KPBMA) is investing in an AI platform for drug development. On the one hand, the Japanese government aims to accelerate R&D and is funding projects that make use of artificial intelligence (AI), is reviving the research-based industry and is promoting drugs of Japanese origin in global markets. Thus, there is growing demand for mass flow controllers in the country. At the same time, the economy is facing challenges, the population is ageing, punitive pricing schemes are impacting smaller, domestic companies and the government has set a target of 80% generic substitution by 2020.
In China, innovation is spurred by several conditions, the sheer size of the population, an increase in lifestyle diseases, the shift away from state-ownership of enterprises, and the government’s investment in healthcare and regulatory reviews. Tempering this, the country relies almost exclusively on generics, thus there is a mass production of API in China, which will not only be consumed within the country but also be exported across the world which will gain momentum to the pharmaceutical mass flow controller market in the country.
About Us:
DataM Intelligence was incorporated in the early weeks of 2017 as a Market Research and Consulting firm with just two people on board. Within a span of less than a year, we have secured more than 100 unique customers from established organizations all over the world.
For more information:
Sai Kiran
Sales Manager at DataM Intelligence
Email: [email protected]
Tel: +1 877 441 4866
Website: www.datamintelligence.com
